↓ Skip to main content

Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy

Overview of attention for article published in Frontiers in oncology, June 2023
Altmetric Badge

Mentioned by

reddit
1 Redditor